Cabaletta Bio, Inc. (CABA)

12.41 +1.76 (+16.58%) 收市：04:00PM EDT

Cabaletta Bio, Inc.

2929 Arch Street
Suite 600
Philadelphia, PA 19104
United States
267 759 3100
https://www.cabalettabio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 101

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Steven A. Nichtberger M.D.	Co-Founder, Chairman, CEO & President	970.6k	無	1961
Dr. Gwendolyn K. Binder Ph.D.	President of Science & Technology	692.99k	無	1975
Dr. David J. Chang FACR, M.D., M.P.H.	Chief Medical Officer	676.74k	無	1963
Dr. Michael C. Milone M.D., Ph.D.	Co-Founder & Co-Chair of Scientific Advisory Board	無	無	無
Dr. Aimee Payne M.D., Ph.D.	Co-Founder & Co-Chair of Scientific Advisory Board	無	無	無
Mr. Anup Marda M.B.A.	Chief Financial Officer	548.2k	無	1978
Dr. Samik Basu M.D.	Chief Scientific Officer	無	無	無
Mr. Michael Gerard J.D.	General Counsel & Secretary	無	無	1980
Ms. Heather Harte-Hall M.Sc.	Chief Compliance Officer	無	無	無
Ms. Martha O'Connor	Chief Human Resources Officer	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

公司管治

截至 2024年4月29日 止，Cabaletta Bio, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：6；董事會：9；股東權利：10；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。